Resectable Nsclc

Perioperative Nivolumab in Resectable NSCLC | NEJM

Clinical case review for the definition of resectable NSCLC

Neoadjuvant, Adjuvant, or Both: Individualized Perioperative Immunotherapy in Resectable NSCLC

PeerView Oncology

8 in 8 Series: Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLC

ThoracicSurgeons

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC

PeerView Oncology

Expert report on neoadjuvant immune checkpoint inhibitors for NSCLC

European Society for Medical Oncology (ESMO)

RESECTABLE NSCLC AND THE IMPORTANCE OF GUIDELINE-RECOMMENDED MOLECULAR TESTING

Lung Cancer Connect, sponsored by AZ Oncology

SQUAT: neoadjuvant chemo-immuno-radiation and surgery in NSCLC

Clinical trials of neoadjuvant targeted therapy in resectable NSCLC

AACR 2023 highlights on advances in the neoadjuvant treatment of resectable NSCLC with John Heymach

European Society for Medical Oncology (ESMO)

PRINCEPS study: atezolizumab for resectable NSCLC

Early-Stage Resectable NSCLC: A Shifting Landscape With Targeted Therapies and Immunotherapy

Maximizing the Impact of EGFR-Targeted Therapy in Resectable NSCLC

PeerView Oncology

Multidisciplinary consensus for the definition of resectable NSCLC

FDA Approves Durvalumab / Imfinzi for Resectable NSCLC Non-Small Cell Lung Cancer

Improving Survival and Cure Rates in Resectable NSCLC With Perioperative Immunotherapy

PeerView Oncology

The latest trends in the management of oncogene-driven resectable NSCLC

Rational for neoadjuvant ICI-based therapy in oncogene-driven resectable NSCLC

How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans in Resectable NSCLC

PeerView Oncology

STS Webinar: Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLC

ThoracicSurgeons